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Abstract Osteosarcoma (OS), the most common primary
bone malignancy, occurs primarily in adolescents and
young adults. In earlier genome-wide association studies,
rs7591996, rs10208273, rs17206779 and rs1906953 were
identified as candidate loci for OS in Caucasians but the
association of these single-nucleotide polymorphisms
(SNPs) with OS in a Chinese Han population remains
unknown. We measured the frequency of these four vari-
ants in a Chinese Han population to better understand the
genetic etiology of OS. Polymerase chain reaction
sequencing was used to detect the genotypes of four can-
didate SNPs in peripheral blood samples collected from
168 OS patients and 216 healthy controls. Logistic
regression models were used to estimate the odds ratios and
95 % confidence intervals. We found rs1906953 in the
glutamate receptor metabotropic 4 (GRM4) gene was
associated significantly with OS in our Chinese Han pop-
ulation; as with the other SNPs, however, no statistically
significant difference was detected. Further analysis
showed the association between rs1906953 and OS was
independent of gender and age. The rs1906953 locus was
not associated with Enneking stages or tumor location;
however, it was associated significantly with OS metastasis
and prognosis. The GRM4 gene polymorphism was asso-
ciated with the susceptibility and metastasis of OS in a
Chinese Han population.
Keywords Osteosarcoma  Single-nucleotide
polymorphisms  Susceptibility  GRM4
Introduction
Osteosarcoma (OS) is the most common primary malignant
bone tumor in children and young adults with a peak
incidence in adolescence and a second smaller peak after
age 50, affecting approximately four people per million
annually in the USA [1, 2]. The metaphyseal regions of the
long bones, including the distal femur, proximal tibia and
proximal humerus, which are capable of rapid growth, are
most likely to be affected [3]. Primary OS arises from
primitive mesenchymal cells producing osteoid and later
extends to the pulmonary region forming secondary tumors
in 10–20 % of patients [4, 5]. Although neoadjuvant che-
motherapy and surgical techniques have improved the
5-year survival of OS patients from 20–30 to 70 %, the
level of OS treatment has not obtained a significant
improvement in recent years and 30 % of newly diagnosed
patients eventually died of lung metastasis [6–9]. There
have been extensive studies of OS genetics, biology,
pathology and clinical aspects in recent years but there has
been little progress in our understanding of its pathogenesis
and therapeutic effect [10]. Therefore, it is important to
study OS-related risk factors and to identify the underlying
mechanism in order to be of great benefit to the reduction
of morbidity and mortality of the disease.
No predisposing factor is known to be related to OS.
The combined effect of genetic and environmental factors
has an important role in the pathogenesis of OS. Genome-
wide linkage analysis has been extremely limited in studies
of polygenic diseases such as OS; so, using single-nucle-
otide polymorphism (SNP) as a molecular genetic marker
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is expected to predict disease susceptibility to guide indi-
vidual treatment. Earlier studies identified many putative
genetic susceptibility variants for increasing OS risk in
diverse biologically plausible pathways [11–22], including
growth and DNA repair; however, the statistical power of
these studies has been limited by small sample sizes [23].
Data regarding the role of common genetic variation in OS
risk are also sparse.
Methods for the analysis of genome-wide association
studies (GWAS) have been promoted greatly by the HapMap
Project data [24]. GWAS are an examination of genome-
wide common genetic variants in different individuals to find
disease or quantitative trait-related variants. Recently,
GWAS in large samples of Caucasians recruited by Savage
et al. [25] identified two novel susceptibility loci for OS. In
the combined samples, the two novel SNPs (rs1906953 and
rs7591996) showed unequivocal evidence of association
with OS, with a genome-wide significance threshold of
P = 5 9 10-8. Moreover, the other SNPs (rs10208273 and
rs17206779) nearly met the genome-wide significance level
for association with OS (P = 2.9 9 10-7 and 5.1 9 10-7).
The above four SNPs are associated with OS in Caucasians,
but whether they are associated with the incidence of OS in a
Chinese Han population has not been estimated. We inves-
tigated the association between rs1906953, rs7591996,
rs10208273 and rs17206779 polymorphisms and OS sus-
ceptibility in a Chinese Han population.
Materials and methods
Study design and population
OS cases (n = 168) in this study were recruited from the
Sixth Affiliated Hospital of Shanghai Jiao Tong University
School of Medicine, and all were diagnosed by postoperative
histopathological examination. The 216 cancer-free control
subjects were chosen from healthy physical examinees.
Blood samples of subjects were collected at orthopedic
surgery departments between 2008 and 2012, and detailed
information about tumor location, stage and histological type
of OS was obtained from medical records. All patients were
followed up regularly (every 24 months); their survival time,
date of death and last follow-up time were recorded. All
individuals were self-described as Chinese Han. The insti-
tutional review boards of Shanghai Jiao Tong University
approved the protocol for this study, and written consent was
obtained from all subjects.
Genomic DNA extraction and genotyping assays
Genomic DNA was extracted from blood specimens using a
Fujifilm QuickGene-610L system according to the
manufacturer’s protocol. A spectrophotometer was used to
measure the concentration of DNA, which was then stored at
-20 C. Sequence information for four candidate SNPs
(rs7591996, rs10208273, rs17206779 and rs1906953) was
obtained from the National Center for Biotechnology
Information (NCBI) SNP database (http://www.ncbi.nlm.
nih.gov/snp/). Sequences containing the four candidate
SNPs were amplified by polymerase chain reaction (PCR)
using high-fidelity Taq polymerase (Roche) with appropriate
primers (Table 1). All PCR products were purified and
sequenced with an ABI 377 DNA Sequencer. Genotype
analysis was done with GENESCANTM and GENOTY-
PERTM software. Genotype results were recorded and
entered into the computer separately by two researchers.
Statistical analysis
Pearson’s v2 test was used to detect whether the genotype
frequencies deviated from the Hardy–Weinberg equilibrium
(HWE) in the experimental and control groups for each SNP.
Logistic regression models were used to estimate the odds
ratio (OR) and 95 % confidence intervals (CI) for the strength
of the association with OS risk, respectively. The association
between rs1906953 genotype frequencies and clinicopatho-
logical characteristics of OS was calculated using uncondi-
tional logistic regression and then adjusted for age, gender and
body mass index (BMI). The Kaplan–Meier method was used
to estimate the probability of disease-free survival. Log-rank
analysis was used to assess the significance of the differences
among OS patients with three genotypes of rs1906953 (TT,
TC and CC). Statistical analysis was done with SPSS ver-
sion19.0 statistical software. Differences with P B 0.05 were
considered statistically significant.
Results
Clinical features of the study subjects
The clinical features of the 384 subjects are given in
Table 2. Among the 168 OS patients, 41.67 % (70/168)
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were female and 58.33 % (98/168) were male. The median
age of the OS cases was 20.41 years (range 9–75 years)
and 20.58 years (range 10–78 years) for the controls. The
average BMI was 22.07 (±1.87) kg/m2 for the OS patients
and 21.89 (±1.86) kg/m2 for the controls. Differences of
gender, age and BMI were not statistically significant
between the case and control groups (P = 0.462, 0.572 and
0.262, respectively). All participants were Chinese Han.
Candidate SNPs associated with OS
The four candidate SNPs (rs7591996, rs10208273,
rs17206779 and rs1906953) and incidence risk of OS are
given in Table 3. Genotype distributions of rs7591996,
rs10208273, rs17206779 and rs1906953 were consistent
with HWE in the control group (P = 0.898, 0.689, 0.372
and 0.700, respectively) and in the OS group (P = 0.965,
0.354, 0.537 and 0.763, respectively). As with rs7591996,
rs10208273 and rs17206779 allele frequency distributions,
no statistically significant difference (P = 0.608, 0.639 and
0.548, respectively) was observed between the case and
control groups (Table 3). However, with respect to the
rs1906953 allele frequency distribution, a significant dif-
ference of P = 0.002 was observed between the case and
control groups. The association analysis showed patients
carrying the T allele had a higher risk of OS (OR 1.57;
95 % CI 1.18–2.09) compared to the C allele (Table 2).
Association between rs1906953 genotype frequency
and clinicopathological features in OS patients
A stratified analysis of clinicopathological characteristics
of OS was used to further investigate the relationship
between rs1906953 and the incidence of OS. The results
are given in Table 4. The genotype TT frequency of
Table 2 Comparison of clinical features between the case and con-
trol groups
Variable Case Control P value
No. (n) 168 216
Female [n (%)] 70 (41.67) 82 (37.96) 0.462
Age (years) 20.09 ± 9.32 20.53 ± 11.79 0.737
BMI (kg/m2) 22.07 ± 1.87 21.89 ± 1.86 0.262
Tumor metastasis [n (%)] 34 (20.24)







Table 3 Summary of association results of four SNPs between 168







OR (95 % CI) P value
rs7591996
AA 15 (8.93) 21 (9.72) 0.870
AC 70 (41.67) 94 (43.52)
CC 83 (49.40) 101 (46.76)
A 100 (29.76) 136 (31.48) 1.08 (1.48–0.8) 0.608
C 236 (70.24) 296 (68.52)
rs10208273
AA 28 (16.67) 31 (14.35) 0.823
AG 74 (44.05) 98 (45.37)
GG 66 (39.29) 87 (40.28)
A 130 (38.69) 160 (37.04) 1.07 (1.44–0.8) 0.639
G 206 (61.31) 272 (62.96)
rs17206779
TT 24 (14.29) 35 (16.2) 0.837
TC 74 (44.05) 96 (44.44)
CC 70 (41.67) 85 (39.35)
T 122 (36.31) 166 (38.43) 1.09 (1.47–0.82) 0.548
C 214 (63.69) 266 (61.57)
rs1906953
TT 45 (26.79) 36 (16.67) 0.010
TC 82 (48.81) 101 (46.76)
CC 41 (24.40) 79 (36.57)
T 172 (51.19) 173 (40.05) 1.57 (2.09–1.18) 0.002
C 164 (48.81) 259 (59.95)
Table 4 Association between genotype frequencies of rs1906953
and clinicopathological features in OS patients
Variable n TT TC CC P value
Gender
Female 70 19 (27.14) 33 (47.14) 18 (25.71) 0.924
Male 98 26 (26.53) 49 (50.00) 23 (23.47)
Age
[20 64 15 (23.44) 31 (48.44) 18 (28.13) 0.600
B20 104 30 (28.85) 51 (49.04) 23 (22.12)
Tumor metastasis
Yes 34 15 (44.12) 12 (35.29) 7 (20.59) 0.036
No 134 30 (22.39) 70 (52.24) 34 (25.37)
Enneking stage
I 25 7 (28.00) 12 (48.00) 6 (24.00) 0.696
II 120 32 (26.67) 61 (50.83) 27 (22.50)
III 23 6 (26.09) 9 (39.13) 8 (34.78)
Location
Trunk 17 5 (29.41) 7 (41.18) 5 (29.41) 0.830
Limbs 151 40 (26.49) 75 (49.67) 36 (23.84)
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rs1906953 in tumor metastasis patients (44.12 %) was
greater compared to patients without tumor metastasis
(26.67 %), and the difference in frequency distribution
between genotypes reached significance (P = 0.036). No
significant difference was observed with respect to sex,
age, Enneking stage or tumor location and the rs1906953
genotype.
Association between the rs1906953 genotype
and prognosis of patients with OS
Survival analysis showed that for rs1906953, OS patients
carrying the TT genotype are likely to be correlated with a
poor survival rate (P = 0.0003 by Log-rank analysis;
Fig. 1). Patients carrying the TT genotype had a median
survival time of 18.22 months, and patients with the TC
genotype (20.78 months) and CC genotype (22.81 months)
had the best outcome.
Discussion
Genetic and environmental factors both contribute to the
cause of OS, and genetic background has the most
important role. The finding of more and more susceptibility
loci and genes related to OS in recent years will provide
important insight into the diagnosis of the disease and aid
the design of new preventive and therapeutic strategies for
OS patients. Importantly, we confirmed the earlier finding
that rs1906953 in the glutamate receptor metabotropic 4
(GRM4) gene is associated with OS in the Chinese Han
population through the association analysis, which once
more provides strong evidence for this locus.
We showed for the first time that there is an association
between rs1906953, located in intron 7 of GRM4 at 6p21.3,
and OS in a Chinese Han population. Our results showed
the allele T frequency of the OS case group (51.19 %) was
greater compared to the control group (40.05 %) and those
carrying the TT genotype had a higher risk of OS. GRM4 is
a family of G protein-coupled receptors that encode the
group III metabotropic glutamate receptor 4 (mGluR4), and
its role in intracellular signaling and inhibition of the cyclic
AMP (cAMP)-signaling cascade has been reported [26,
27].
The important role of glutamate in intercellular com-
munication in the central nervous system (CNS) has been
extended in recent years to non-neural systems [28–30].
The glutamate-signaling system has been shown to be
essential in bone remodeling and homeostasis [29, 31, 32].
The disrupted normal glutamate signaling aggravates sev-
eral bone diseases. Numerous cancers, including breast,
prostate and lung, that can metastasize to bone have been
shown to express several glutamate receptors and trans-
porters [33, 34]. Human OS cell lines expressing several
glutamate receptors are known to be associated with proper
tumor cell function because inhibited glutamate receptors
lead to limited cell growth and pharmacologic prevention
of glutamate release that results in blocked differentiation
and increased levels of apoptosis [35]. The important role
of the cAMP pathway in OS has been demonstrated in
mice, in which a cAMP-dependent protein kinase (Prkar1a)
has been shown to suppress OS tumor growth [36, 37].
Together, these results suggest GRM4 is implicated in OS.
The reference SNP (rs1906953) is located in intron 7 of
GRM4, which is expressed abundantly in nerve tissue
(including brain, spinal cord and retina) and relatively little
in other tissues. To further test whether the OS-associated
SNPs regulate the expression of GRM4, we inspected three
cis-gene expression quantitative trait loci (cis-eQTL) dat-
abases of European Caucasian populations [38–40] and
found rs1906953 was not correlated with the expression of
GRM4 or other genes. The index SNP, rs1906953, maps to
a DNase I hypersensitive region based on the Encyclopedia
of DNA Elements (ENCODE) data set, raising the distinct
likelihood that the variant is within a region accessible to
open chromatin and could manifest active regulatory ele-
ments [41].
Several studies have suggested OS has a high incidence in
young children and males of all ages and is often located in
long tubular bones [42]. The results of some studies suggested
being taller than average and with a greater birth weight at
diagnosis are associated with increased OS risk [43–45].
Therefore, we analyzed the association of rs1906953 with
some clinical parameters, including gender, age, location and
distant metastasis. The genotype of rs1906953 is associated
with the susceptibility of OS in our study, but not specifically
Fig. 1 Analysis for effects of the rs1906953 genotype on survival of
the OS group
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to cases with different gender, age and location of the tumor.
This indicates GRM4 is involved in signaling pathways that
stimulate the formation of OS independent of gender, age and
location.
Distant metastasis association analysis showed the
genotype of rs1906953_TT was correlated significantly
with metastasis of OS. Survival analysis showed for
rs1906953 that the median survival time of OS patients
with the TT genotype was significantly shorter compared to
the TC and CC genotypes. This result is consistent with
several earlier findings that GRM4 expressed in human OS
cells is associated with its proper function and its expres-
sion in pediatric CNS tumors, rhabdomyosarcoma, multiple
myeloma and colorectal cancer is predicted with poor
prognosis [35, 46–49]. Therefore, molecular biological
studies are needed to confirm these two findings. On the
basis of these results, we suggest GRM4-related signaling
is involved in the metastasis of OS and affects the survival
of OS patients; however, more studies of the underlying
molecular and biological mechanisms are needed to further
confirm these results.
In summary, we showed the GRM4 gene polymorphism
rs1906953 is associated with the incidence of OS and with
the metastasis and survival of OS patients in a Chinese Han
population. There are some limitations in our case–control
study. Because all patient cases in this study were recruited
from one hospital, it is difficult to avoid the inherent
selection bias. In addition, because of the low incidence of
OS, the number of OS patients in the study is small, which
makes the statistical power of our results low. Therefore,
studies with greater numbers of patients are needed to be
confident that the GRM4 gene polymorphism rs1906953 is
a genetic marker in predicting the incidence and prognosis
of OS in a Chinese Han population.
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